| Description | Purity>95% by SDS-PAGEExtinction CoeffA280 nm = 1.27 at 1.0 mg/mLGeneral DescriptionFactor Ba is the fragment of complement factor B that results from activation of the alternative pathway. Prepares the factor Ba fragment from factor B which was purified from normal human serum. Complement factorPurity>95% by SDS-PAGEExtinction CoeffA280 nm = 1.27 at 1.0 mg/mLGeneral DescriptionFactor Ba is the fragment of complement factor B that results from activation of the alternative pathway. Prepares the factor Ba fragment from factor B which was purified from normal human serum. Complement factor B is a glycosylated protein composed of a single 93,000 Da polypeptide chain. Factor B is anessential component of the alternative pathway of complement activation and is found in plasma at approximately 200 µg/mL. In the presence of Mg++ factor B binds to C3b and the C3b,B complex can be activated by factor D, a serine protease that circulates as an active trypsin-like serine protease. Cleavage of factor B by factor D causes the release of the Ba fragment (33,000 Da) and leaves the 60,000 Bb fragment bound to C3b. This Ba fragment comes from the N-terminal of factor B and it contains three CCP domains which interact with C3b (Morley, B.J. and Walport, M.J. (2000)). The isolated fragment Ba has been reported to have a weak affinity for C3b and to inhibit the interaction of factor B with C3b thus inhibiting the activation of the alternative pathway (Pryzdial, E.L.and Isenman, D.E., (1987)).The fragments of factor B (Ba and Bb) have been proposed to elicit several biological responses. See the section titled Function below and in the product description for the Bb fragment.FunctionThe fragments of factor B (Ba and Bb) have been proposed to elicit numerous biological responses; however, many of these activities have proved to be controversialwith an inconsistent record of reproducibility. It is not yet clear whether these failures are due to different experimental conditions, more highly purified Ba and Bb than available in the early days or the need to test fresh, in situ-prepared fragments, as has been suggested. Both fragments Ba and Bb have been reported to bind to B lymphocyte receptors and modulate proliferation (Kolb, W.P., et al. (1989)). Ba, but not Bb, was shown to exhibit growth-supporting activity for activated murine B lymphocytes (Praz, F. and Ruuth, E. (1986)). On the other hand, Ba has been reported to inhibit human B cell prolifieration (Ambrus, J.L. et al. (1990)). The small fragment Ba has been reported to show chemotactic activity with neutrophils and macrophages, but this effect is so much lower than that of C5a or even C5adesArg that its effect in vivo may be negligible (Morgan, B.P., (1990)). In a study of smooth muscle contractile activity, neither Ba nor Bb caused contraction of guinea pig ileum (a sensitive test for C5a) or histamine release from rat mast cells, but Ba caused guinea pig PMN to increase chemotactic activity (Hamuro, J., et al. (1978)).AssaysThere are no convenient assays for the biological activity of Ba. Several companies produce ELISA kits for measuring Ba levels in blood samples (Dodds, A.W. and Sim, R.B. (1997)).ApplicationsSplit products of factor B in plasma are indicative of activation of the alternative pathway in vivo. ELISA kits for measurement of Ba and Bb are commercially available. These have been used in numerous human and animal studies (Lynch, A.M., et al. (2008)). See In vivo section below.In vivoThe average concentration of factor B in blood is 200 µg/mL (range 170-258 µg/mL) in human plasma. Factor B is an acute phase protein whose plasma levels increases during inflammation. The fragments Ba and Bb are released upon activation of the alternative pathway and circulate in blood until cleared (Lynch, A.M., et al. (2008)). Baseline levels in normals have been reported to be 29 ng Ba/mL (0.015% of the factor B concentration). The concentration of fragment Ba in patients with tubular proteinuria was found to be elevated more than 100-fold (4800 ng/mL)(Oppermann, M. et al. (1991)). There was a minimal increase in the plasma concentration of fragment Bb in these patients.GeneticsThe gene for factor B is located on human chromosome 6p21.3 within the MHC class III region between the class I and class II regions. The factor B gene lies between the larger gene for C2 (to which it is highly homologous) and genes for C4A and C4B. The gene is composed of 18 exons and spans 6 kb.DeficienciesNo natural deficiencies of factor B have been identified in humans or animals.Mice deficient in factor B (B-/- mice), compared to wild-type, exhibit much lower or no pathology in a wide variety of diseases where alternative pathway activation is the cause of or exacerbates the pathology of these diseases. See Diseases section below. Acquired and secondary deficiencies do occur in humans. Human factor I deficiencies exhibit very low factor B levels due to the fact that C3b is not inactivated in the absence of factor I and C3b accumulates in blood. This results in binding of factor B, cleavage by factor D and rapid release of fragments Ba and Bb. Transfusions with normal plasma or reconstitution with factor I temporarily stop or slow production of these fragments.Precautions/Toxicity/HazardsThis protein is purified from human serum and therefore precautions appropriate for handling any blood-derived product must be used even though the source was shown by certified tests to be negative for HBsAg, HTLV-I/II, STS, and for antibodies to HCV, HIV-1 and HIV-II.Hazard Code: B WGK Germany 3MSDS available upon request... Read More | Product DescriptionEndo F1 cleaves Asparagine-linked high mannose and some hybrid oligosaccharides. Core fucosylation reduces the activity by 50 fold. Endoglycosidase F1 will hydrolyze sulfate containing high-mannose chains. It cleaves between the two N-acetylglucosamine residues in the Product DescriptionEndo F1 cleaves Asparagine-linked high mannose and some hybrid oligosaccharides. Core fucosylation reduces the activity by 50 fold. Endoglycosidase F1 will hydrolyze sulfate containing high-mannose chains. It cleaves between the two N-acetylglucosamine residues in the diacetylchitobiose core of the oligosaccharide, generating a truncated sugar molecule with one N-acetylglucosamine residue remaining on the asparagine. In contrast, PNGase F removes the oligosaccharide intact.Molecular weight 32,000 daltonsContents60 µl aliquot of enzyme (1 U) in 20 mM Tris-HCl, pH 7.5Included with 20 µL and 60 µL pack sizes:5x Reaction Buffer – 250 mM sodium phosphate, pH 5.5Specific ActivityDefined as the amount of enzyme required to catalyze the release of N-linked oligosaccharides from 1 micromole of denatured Ribonuclease B (RNase B) in 1 minute at 37°C, pH 5.5. Cleavage is monitored by SDS-PAGE (cleaved RNase B migrates faster).FormulationThe enzyme is provided as a sterile-filtered solution in 20 mM Tris-HCl, pH 7.5StabilitySeveral days exposure to ambient temperatures will not reduce activity. Stable at least 12 months when stored properly. SpecificityEndo F1 cleaves Asparagine-linked high mannose or hybrid oligosaccharides. It cleaves between the two N-acetylglucosamine residues in the diacetylchitobiose core of the oligosaccharide, generating a truncated sugar molecule with one N-acetylglucosamine residue remaining on the asparagine. In contrast, PNGase F removes the oligosaccharide intact. Quality & PurityEndo F1 is tested for contaminating protease as follows: 10 µg of denatured BSA is incubated at 37°C for 24 hours with 2 µl of enzyme. SDS-PAGE analysis of the treated BSA shows no evidence of degradation. The production host strain has been extensively tested and does not produce any detectable glycosidases.Directions for use1. Add up to 200 µg of glycoprotein to an Eppendorf tube. Adjust to 38 µl final volume with de-ionized water.2. Add 10 µl 5x Reaction Buffer 5.53. Add 2.0 µl of Endo F1 to the reaction. Incubate 1 hour or more at 37°C.Monitor cleavage by SDS-PAGE... Read More | Heme Oxygenase-1-IN-1 (Compound 2) is a heme oxygenase 1 ( HO-1 ) inhibitor with an IC 50 of 0.25 µMIC50& Target:IC 50 : 0.25 µM (HO-1) | Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptorIn VitroProtease-Activated Protease-Activated Receptor-1, PAR-1 Agonist is a selective proteinase-activated receptor1 (PAR-1) agonist peptide. Protease-Activated Receptor-1, PAR-1 Agonist corresponds to PAR1 tethered ligand and which can selectively mimic theactions of thrombin via this receptorIn VitroProtease-Activated Receptor-1, PAR-1 Agonist induces activation of protein kinase C isoenzymes alpha and epsilon in human HT-29 colon carcinoma cells expressing PAR1 endogeneously. On the cellular level, Protease-Activated Receptor-1, PAR-1 Agonist and thrombin prompted HT-29 cell migration and matrix adhesion by a PKCepsilon-dependent mechanism as concluded because of the inhibition of PAR1-mediated effects by the PKC inhibitor bisindolylmaleimide I and the PKCepsilon translocation inhibitory peptide EAVSLKPT but not by the PKC inhibitor Gö 6976. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:PAR-1... Read More | Inquire |